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Effects of Aspirin Responsiveness
and Platelet Reactivity on Early Vein Graft
Thrombosis After Coronary Artery Bypass Graft Surgery
Tyler J. Gluckman, MD,* Rhondalyn C. McLean, MD,* Steven P. Schulman, MD,*
Thomas S. Kickler, MD,* Edward P. Shapiro, MD,* John V. Conte, MD,†
Kathleen W. McNicholas, MD,‡ Jodi B. Segal, MD,* Jeffrey J. Rade, MD*
Baltimore, Maryland; and Christiana, Delaware
Objectives The purpose of this study was to determine if an incomplete response to or inadequate antiplatelet effect of aspirin,
or both, contribute to saphenous vein graft (SVG) occlusion after coronary artery bypass graft (CABG) surgery.
Background Thrombosis is the predominant cause of early SVG occlusion. Aspirin, which inhibits cyclooxygenase-1 activity
and thromboxane generation in platelets, reduces early SVG occlusion by one-half.
Methods Aspirin responsiveness and platelet reactivity were characterized 3 days and 6 months after coronary artery bypass
graft surgery in 229 subjects receiving aspirin monotherapy by platelet aggregation to arachidonic acid, adenosine
diphosphate, collagen and epinephrine, Platelet Function Analyzer-100 (Siemens Healthcare Diagnostics, Newark,
Delaware) closure time (CT) using collagen/epinephrine agonist cartridge and collagen/adenosine diphosphate
(CADP) agonist cartridge, VerifyNow Aspirin assay (Accumetrics, Inc., San Diego, California), and urine levels of 11-
dehydro-thromboxane B2 (UTXB2). SVG patency was determined 6 months after surgery by computed tomography
coronary angiography.
Results Inhibited arachidonic acid-induced platelet aggregation, indicative of aspirin-mediated cyclooxygenase-1 suppres-
sion, occurred in 95% and 99% of subjects 3 days and 6 months after surgery, respectively. Despite this, 73%
and 31% of subjects at these times had elevated UTXB2. Among tested parameters, only UTXB2 and CADP CT
measured 6 months after surgery correlated with outcome. By multivariate analysis, CADP CT of 88 s (odds
ratio: 2.85, p  0.006), target vessel diameter of 1.5 mm (odds ratio: 2.38, p  0.01), and UTXB2 of 450
pg/mg creatinine (odds ratio: 2.59, p  0.015) correlated with SVG occlusion. CADP CT and UTXB2 in combina-
tion further identified subjects at particularly high and low risk for SVG occlusion.
Conclusions Aspirin-insensitive thromboxane generation measured by UTXB2 and shear-dependent platelet hyper-reactivity
measured by Platelet Function Analyzer-100 CADP CT are novel independent risk factors for early SVG thrombo-
sis after coronary artery bypass graft surgery. (J Am Coll Cardiol 2011;57:1069–77) © 2011 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.08.650Coronary artery bypass graft (CABG) surgery is a com-
monly used revascularization strategy in patients with severe
coronary artery disease. Saphenous vein grafts (SVGs) are
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accepted August 18, 2010.the most frequently used conduits for this procedure. Unlike
arterial grafts, SVGs are particularly susceptible to occlusive
thrombosis during the first post-operative year, which
exposes patients to increased risks of death, myocardial
infarction, and repeat revascularization (1–3).
See page 1078
Aspirin (ASA) is the pharmacologic agent most convinc-
ingly shown to prevent SVG thrombosis, reducing its
incidence during the first postoperative year by nearly 50%
(4). The principal effect of ASA is to suppress agonist-
induced platelet activation by irreversibly inhibiting platelet
cyclooxygenase (COX)-1, a critical enzyme regulating the
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Aspirin and Vein Graft Thrombosis March 1, 2011:1069–77generation of thromboxane A2
(TXA2) from arachidonic acid
(5). As a strong platelet agonist,
TXA2 not only mediates activa-
tion of the platelet in which it
was formed, but also its release
activates adjacent quiescent plate-
lets and causes arterial vasocon-
striction by binding to cellular
thromboxane receptors.
Recent studies indicate that
some patients, particularly those
with cardiovascular disease, ex-
hibit an incomplete or inade-
quate antiplatelet effect by ASA
characterized by persistent TXA2
generation and high platelet re-
activity assessed by ex vivo plate-
let assays (6). Such patients, vari-
ably referred to as being ASA resistant, ASA nonresponsive,
or more recently as having high on-treatment platelet
reactivity, are at increased risk for adverse cardiac events
compared with those with suppressed platelet reactivity and
TXA2 generation (7–9). Patients undergoing CABG sur-
ery have been reported to have decreased ASA responsive-
ess early in the post-operative period (10,11), although the
ffect of this on clinical outcome remains unclear. The goal
f the present study was to determine if an incomplete
esponse to or an inadequate antiplatelet effect of ASA, or
oth, contribute to early SVG occlusion after CABG
urgery.
ethods
atient population. The Reduction in Graft Occlusion
ates (RIGOR) study is a multicenter study of patients
ndergoing first-time CABG surgery designed to investi-
ate the effects of antiplatelet factor 4/heparin antibody
nduction on SVG occlusion. A detailed description of the
tudy and its principal findings have been reported previ-
usly (12). A second prospectively defined objective of the
tudy was to determine whether ASA resistance, platelet
yper-reactivity, or both, also contribute to early SVG
hrombosis.
Patients 18 years of age or older undergoing first-time
ABG surgery with implantation of 1 or more SVGs were
ligible for enrollment. Although patients with an antici-
ated requirement for post-operative oral anticoagulation or
on-ASA antiplatelet therapy were excluded, those admin-
stered such agents for unforeseen post-operative conditions
emained in the study. All subjects were administered ASA
300 to 325 mg) within 24 h of surgery and were given a
upply of 325 mg enteric-coated ASA at discharge and
nstructed to take 1 pill daily unless directed otherwise by
Abbreviations
and Acronyms
ASA  aspirin
CABG  coronary artery
bypass graft
CADP  collagen/
adenosine diphosphate
CEPI  collagen/
epinephrine
COX  cyclooxygenase
CT  closure time
IQR  interquartile range
SVG  saphenous vein
graft
TXA2  thromboxane A2
UTXB2  urinary 11-
dehydro-thromboxane B2heir physician. Pill counts were performed at each postop- prative encounter. ASA responsiveness and platelet reactiv-
ty were measured in subjects enrolled at the Johns Hopkins
ospital 2 to 4 days after CABG surgery and in all subjects
months after CABG surgery at the time SVG patency was
ssessed by multidetector computed tomography coronary
ngiography.
easurement of platelet reactivity and ASA responsiveness.
PLATELET AGGREGOMETRY. Platelet-rich plasma was pre-
ared from blood collected in 3.2% citrate by centrifugation
t 100 rpm for 10 min, and the platelet count was adjusted to
80,000/mm3 by the addition of platelet-poor plasma. Undi-
luted samples with a platelet count of 100,000/mm3 were
excluded from analysis. Impedance platelet aggregometry was
performed by stimulation with arachidonic acid (0.5 mM),
adenosine diphosphate (5, 10, and 20 M), epinephrine (50
M), and collagen (1 g/ml) using a Chrono-Log Model
560CA aggregometer (Chrono-Log, Havertown, Pennsyl-
vania). The maximum aggregation response within 5 min-
utes was recorded in . Subjects were considered ASA
responsive if arachidonic acid-induced platelet aggregation
was 1  (normal range in our laboratory for ASA-naïve
subjects: 5 to 17 ).
SHEAR-DEPENDENT PLATELET ACTIVATION. The closure
time (CT) of whole blood collected in 3.8% citrate under
shear was measured by the Platelet Function Analyzer-100
(PFA-100) device (Siemens Healthcare Diagnostics, New-
ark, Delaware), as previously described (13). Samples were
tested with the collagen/epinephrine (CEPI) agonist car-
tridge, which is sensitive to the effects of ASA, and the
collagen/adenosine diphosphate (CADP) agonist cartridge,
which assesses global platelet reactivity, but is not affected
by ASA. Samples from subjects with a platelet count
50,000/m3 were excluded from analysis. Samples with
onclosure were assigned a CT value of 300 s, the maximum
easurable by the device. ASA responsiveness by the
FA-100 assay was defined as a CEPI CT 193 s, the
pper limit of the normal range in our laboratory for
SA-naïve patients (13).
VERIFYNOW ASPIRIN ASSAY. The VerifyNow Aspirin assay
Accumetrics, Inc., San Diego, California) measures arachi-
onic acid-induced platelet aggregation in whole blood
ontaining fibrinogen-coated beads (14). Samples from
ubjects with a platelet count 50,000/m3 were excluded
rom analysis. ASA responsiveness by this assay was defined
s an aspirin reaction unit (ARU) value 550 according to
he manufacturer’s instruction.
MEASUREMENT OF TXA2 GENERATION. TXA2 generation
as quantified by measuring the concentration of its stable
etabolite 11-dehydro-thromboxane B2 (UTXB2) in urine
y enzyme-linked immunosorbent assay and expressed as a
atio to urinary creatinine as previously described (13). ASA
esponsiveness by this assay was defined as UTXB2 400
g/mg creatinine according to established criteria (15).
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March 1, 2011:1069–77 Aspirin and Vein Graft ThrombosisAssessment of SVG patency. SVG patency was assessed 6
months after CABG surgery by multidetector computed
tomography coronary angiography as previously described
(12). Data from clinically driven invasive coronary angio-
grams could be used for the primary end point analysis if
performed within 6 weeks of the anticipated 6-month
follow-up visit or if it was the only assessment of SVG
patency before an adverse clinical end point. Each segment
of Y-grafts and skip grafts were considered as separate
SVGs according to the Society of Thoracic Surgeons
criteria. Reconstructed images were analyzed by 2 blinded
reviewers (T.J.G., E.P.S., or J.J.R.) and were classified as
patent (containing stenoses of 0% to 75%), significantly
diseased (containing stenoses of 76% to 99%), or occluded
(containing a 100% stenosis). There was 98% concordance
in assessment of SVG patency between reviewers. In cases
of discordance, a third reviewer adjudicated all SVGs in that
patient.
Statistical analysis. Data from subjects who survived the
index hospitalization, underwent angiographic assessment
of SVG patency, and were maintained throughout the study
period on ASA as the only antiplatelet agent were analyzed
for the outcome of SVG occlusion versus patency. For
statistical purposes, the small number of SVGs classified as
significantly diseased were classified as patent. Demographic
differences between patients with and without occluded
SVGs were evaluated using a Student t test for mean values
or Wilcoxon rank-sum test for medians as appropriate for
the data distribution. Proportions were compared using a
chi-square or Fisher exact test and comparisons among
groups were carried out with an analysis of variance, the
McNemar test, or the Kruskal-Wallis test, as appropriate.
Univariate analyses were performed on a per graft basis
for the odds of occlusion versus patency using those vari-
ables deemed biologically plausible or supported by the
literature. Categorical covariates were tested for collinearity
using chi-square or Fisher exact tests, whereas continuous
variables were tested using Pearson’s correlation coefficients.
Highly correlated covariates (e.g., rho 0.7) were elimi-
nated based on clinical significance. Variables with statisti-
cal significance of p  0.15 in the univariate analysis or
hose supported by the literature were entered into a
ultilevel random effects model. A 4-level model was
xplored initially: analyzing SVG outcome with random
ntercepts for patient, surgeon, hospital, and multiseg-
ented SVGs (i.e., skip grafts and Y-grafts) considered as
ingle grafts. Because random intercepts on surgeon, hos-
ital, and multisegmented SVGs were not significant, the
nalysis thereafter included clustering on patient alone.
tepwise backwards elimination of variables was performed
o generate several potential models. Akaike Information
riterion was used for model comparison.
Analyses were performed using Stata/MP version 10.0
or Windows software (Stata, Inc., College Station, Texas).
ifferences were considered significant when p  0.05.esults
tudy population characteristics. The RIGOR study en-
olled 368 subjects undergoing first-time CABG surgery
ith implantation of 1 SVG. The study population was
epresentative of patients undergoing isolated CABG sur-
ery based on comparison with the Society of Thoracic
urgeons National Database (12). Two hundred twenty-
ine subjects who survived the index hospitalization, under-
ent angiographic assessment of SVG patency and were
aintained on ASA throughout the study period as the only
ntiplatelet agent were included in the present analysis (Fig. 1).
n addition to major differences in antiplatelet regimens and
ngiographic follow-up, subjects included in the analysis were
ore likely to be men, to be referred electively for CABG
urgery, to have a slightly lower median euroSCORE and
revalences of current tobacco use, and to have a history of
trial fibrillation than excluded subjects (Supplemental Ta-
le 1). The baseline, operative, and post-operative charac-
eristics of subjects with at least 1 occluded SVG were very
imilar to those with patent SVGs, except that the former
roup underwent implantation of 4 SVGs more frequently
Table 1). Of the 497 SVGs implanted in these subjects
median: 2, range: 1 to 6 SVGs/subject), 94 (19%) were totally
ccluded when assessed a median of 189 days (interquartile
ange [IQR]: 182 to 203 days) after CABG surgery. Only 9
VGs (2%) contained high-grade (75%) stenoses, consistent
ith the concept that thrombosis and neither atherosclerosis
or neointima hyperplasia is the predominant cause of early
368 subjects enrolled
363 survived Index 
hospitalization
68  SVG patency not assessed 
• 5 no intravenous access
• 7 preclusive medical 
condition
• 8 died prior to scheduled CTA
• 48 declined CTA
295 with angiographic 
assessment of SVG patency
• 276 CTA
• 16 invasive angiography
• 4 MR angiography  
66 not on ASA 
monotherapy
• 64 on thienopyridine 
• 2 not on ASA
229 on ASA monotherapy 
throughout study
Figure 1 Schematic of RIGOR Study
Enrollment and Analysis Criteria
ASA  aspirin; CTA  multidetector computed tomography coronary angiography;
MR  magnetic resonance; RIGOR  Reduction in Graft Occlusion Rates;
SVG  saphenous vein graft.
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Aspirin and Vein Graft Thrombosis March 1, 2011:1069–77SVG failure. Seventy subjects (31%) had occlusion of1 SVG
nd 21 subjects (9%) had occlusion of all implanted SVGs.
revalence of ASA nonresponsiveness after CABG surgery.
latelet function testing was performed on 168 subjects a
edian of 3 days (IQR: 3 to 4 days) and on all 229 subjects
median of 189 days (IQR: 182 to 203 days) after CABG
Baseline, Operative, and Post-OperativeCharacteristics of Subjects Stratified by SVG PaTable 1 Baseline, Operative, an Post-OperCharacteristics of Subjects Stratifie
Age, yrs
Men
White race
Body mass index, kg/m2
Medical history
Hypertension
Hyperlipidemia
Diabetes
Heart failure
Peripheral/cerebrovascular disease
Atrial fibrillation
Current tobacco use
Creatinine, mg/dl
Myocardial infarction
Within 7 days
Prior percutaneous coronary intervention
Pre-operative ejection fraction
30%
30% to 50%
50%
Number of coronary arteries with 50% stenosis
2
3
Left main with 50% stenosis
Elective CABG surgery
Isolated CABG surgery
EuroSCORE
Cardiopulmonary bypass
Duration, min
Arterial graft implanted
Number of SVGs per subject
1
2
3
4
SVG skip graft implanted
SVG patency assessment, post-operative day
Medications at time of SVG patency assessment
ASA
325 mg/day
Non-ASA antiplatelet agent
Oral anticoagulation
ACE inhibitor/ARB
Beta-blocker
Lipid-lowering agent
Values are median (interquartile range) or n (%). *p  0.008.
ACE  angiotensin converting enzyme; ARB  angiotensin re
SVG  saphenous vein graft.urgery. UTXB2 was measured in 219 and 228 subjects at whese same respective time points. Of the assays performed,
have definable thresholds limits for ASA responsiveness.
he prevalence of ASA nonresponsiveness varied widely by
ssay and by time after CABG surgery (Fig. 2A). By
rachidonic acid-induced platelet aggregation, a specific
easure of platelet COX-1 activity, ASA nonresponsiveness
y
SVG Patency
>1 Occluded SVG
(n  70)
Patent SVGs
(n  159)
63 (55–72) 63 (57–71)
52 (74%) 135 (85%)
57 (81%) 144 (91%)
30 (27–34) 29 (26–32)
53 (76%) 134 (84%)
56 (80%) 135 (85%)
20 (29%) 64 (40%)
6 (9%) 24 (15%)
13 (19%) 30 (19%)
1 (1%) 6 (4%)
20 (29%) 32 (20%)
1.0 (0.9–1.2) 1.0 (0.8–1.1)
28 (40%) 61 (38%)
16 (23%) 29 (18%)
11 (16%) 34 (21%)
4 (6%) 16 (10%)
22 (31%) 54 (34%)
44 (63%) 89 (56%)
11 (16%) 21 (13%)
59 (84%) 135 (85%)
27 (39%) 59 (37%)
32 (46%) 66 (42%)
64 (91%) 142 (89%)
4 (2–5) 3 (2–5)
70 (100%) 156 (98%)
80 (65–95) 75 (60–96)
69 (99%) 154 (97%)
14 (20%) 47 (30%)
23 (33%) 73 (46%)
21 (30%) 32 (20%)
11 (17%)* 7 (4%)
13 (19%) 18 (11%)
188 (182–198) 189 (183–202)
70 (100%) 159 (100%)
3 (4%) 16 (10%)
0 (0%) 0 (0%)
3 (4%) 10 (6%)
43 (61%) 110 (62%)
62 (89%) 128 (81%)
60 (86%) 145 (91%)
blocker; ASA  aspirin; CABG  coronary artery bypass graft;tencive
d byas present in 5% of subjects (median aggregation: 5 , IQR:
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March 1, 2011:1069–77 Aspirin and Vein Graft Thrombosis2 to 10) 3 days after surgery and in1% of subjects (median
ggregation: 12 , range 8 to 15 ) 6 months after surgery.
oncurrent nonsteroidal anti-inflammatory drug use did not
orrelate with the presence of ASA nonresponsiveness defined
y this method at either time point (data not shown). ASA
onresponsiveness also was significantly more prevalent imme-
iately after CABG surgery when defined by PFA-100 CT
sing the CEPI agonist cartridge, but remained relatively
onstant over time when assessed by the VerifyNow Aspirin
ssay. Despite a high degree of platelet COX-1 inhibition by
SA, persistent TXA2 generation was observed in 73% and
31% of subjects 3 days and 6 months after CABG surgery,
respectively, as evidenced by often significantly elevated levels
of UTXB2 (Fig. 2B).
Figure 2 Prevalence of ASA Nonresponsiveness by Assay and T
(A) Percentage of subjects with ASA nonresponsiveness 3 days and 6 months aft
impedance aggregometry as arachidonic acid-induced platelet aggregation (AA) 1
Function Analyzer-100 (PFA-100, Siemens Healthcare Diagnostics, Newark, Delawa
thromboxane B2 (UTXB2) 400 pg/mg creatinine. *p  0.001 for 6-month versus
values with interquartile ranges (boxes), 5% and 95% confidence intervals (bars),
denotes threshold for ASA nonresponsiveness (400 pg/mg creatinine). Abbreviatio
Relationship Between Platelet Reactivity and ASA Responsivenessand 6-Month SVG PatencyTable 2 Relationship Between Platelet Reactivity and ASA Reand 6-Month SVG Patency
Assay
Per SVG
Occluded SVG Patent SVG n
Platelet aggregation ()
Arachidonic acid, 0.5 mM 0 (0–0) 0 (0–0) 289
ADP, 5 M 17.1 5.6 18.8 4.9 230
ADP, 10 M 18.0 4.8 18.6 5.1 221
ADP, 20 M 16.5 4.6 16.6 4.4 287
Epinephrine, 50 M 10.7 6.5 9.94 6.56 289
Collagen, 1 g/ml 14.1 5.4 12.7 6.3 289
PFA-100 CT (s)
CEPI 121 (94–203) 136 (101–241) 289
CADP 96 (82–137) 98 (83–145) 305
UTXB2 (ln pg/mg creatinine) 6.42 0.71 6.43 0.65 479
VerifyNow Aspirin (ARU) 475 59 484 60 308
Values are median (interquartile range) or mean  SD.
ADP  adenosine diphosphate; ARU  aspirin reaction unit; CADP  collagen/ADP agonist cartridge; C
Analyzer 100; UTXB2  urine 11-dehydro-thromboxane B2; other abbreviations as in Table 1.ssociation with early SVG occlusion. No laboratory
arameter measured 3 days after CABG surgery could
ifferentiate occluded from nonoccluded SVGs or subjects
ith occluded versus patent SVGs (Table 2). When assessed
months after surgery, however, occluded SVGs were
ssociated with a higher mean level of UTXB2 and lower
edian PFA-100 CADP CT (Table 3). Subjects with 1
ccluded SVG also had a lower median PFA-100 CADP
T than subjects with patent SVGs. Although SVG occlu-
ion was inversely proportional to PFA-100 CADP CT, it
as most prevalent in subjects with UTXB2 450 pg/mg
creatinine (Fig. 3).
The associations of PFA-100 CADP CT and UTXB2 to
arly SVG occlusion then were determined in relationship
After CABG Surgery
nary artery bypass graft (CABG) surgery. ASA nonresponsiveness was defined by
VerifyNow Aspirin test result 550 aspirin reaction units (ARU), by Platelet
llagen/epinephrine (CEPI) closure time (CT) 193 s, and by urinary 11-dehydro-
values. (B) UTXB2 in subjects 3 days and 6 months after CABG surgery. Median
dividual outliers are shown. p  0.001 for differences between groups. Red line
n Figure 1.
asured 3 Days After CABG Surgery,iven ss, Measured 3 Days After CABG Surgery,
Per Subject
p Value >1 Occluded SVG No Occluded SVG n p Value
NS 0 (0–0) 0 (0–0) 154 NS
NS 17.9 5.3 18.9 4.9 124 NS
NS 18.0 4.5 18.7 5.2 118 NS
NS 16.8 4.8 16.6 4.7 153 NS
NS 10.5 6.7 10.4 6.6 154 NS
NS 14.4 5.2 12.9 6.4 154 NS
NS 135 (100–204) 136 (101–263) 156 NS
NS 96 (81–139) 102 (84–146) 162 NS
NS 6.33 0.71 6.47 0.60 219 NS
NS 478 61 484 61 164 NSime
er coro
, by
re) co
3-day
and in
n as i, MeponsEPI  collagen/epinephrine agonist cartridge; NS  not significant; PFA-100  Platelet Function
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Aspirin and Vein Graft Thrombosis March 1, 2011:1069–77to a comprehensive array of known and potential risk
factors. In addition to several patient- and graft-specific
factors, PFA-100 CADP CT and UTXB2 measured 6
Relationship Between Platelet Reactivity and ASA Responsivenessand 6-Month SVG PatencyTable 3 Relationship Between Platelet Reactivity and ASA Reand 6-Month SVG Patency
Assay
Per SVG
Occluded SVG Patent SVG n
Platelet aggregation ()
Arachidonic acid, 0.5 mM 0 (0–0) 0 (0–0) 495
ADP, 5 M 17.5 5.2 17.7 4.7 463
ADP, 10 M 17.5 4.7 18.0 4.9 457
ADP, 20 M 16.1 5.3 17.1 4.7 483
Epinephrine, 50 M 5.47 5.59 5.23 6.33 490
Collagen, 1 g/ml 14.3 5.6 14.9 5.2 495
PFA-100 CT (s)
CEPI 288 (245–300) 295 (260–300) 491
CADP 80 (72–98) 88 (77–106) 492
UTXB2 (ln pg/mg creatinine) 5.98 0.63 5.76 0.55 495
VerifyNow Aspirin (ARU) 450 51 458 60 496
Values are median (interquartile range) or mean  SD.
Abbreviations as in Tables 1 and 2.
Figure 3 Prevalence of SVG Occlusion by PFA-100 CADP CT
and UTXB2
Percentage of occluded SVGs in subjects stratified by quartiles of (A) PFA-100
collagen/adenosine diphosphate (CADP) CT and (B) UTXB2 measured 6
months after CABG surgery. Abbreviations as in Figures 1 and 2.onths after CABG surgery correlated with early SVG
cclusion by univariate analysis (Supplemental Tables 2 to 5)
hen expressed both as continuous variables and as binary
ariables based on respective median (88 s) and upper quartile
alues (450 pg/mg creatinine). When analyzed either as con-
inuous (model 1) or binary (model 2) variables in multivariate
nalyses (Table 4), PFA-100 CADP CT and UTXB2 re-
mained significantly associated with SVG outcome along with
target vessel diameter1.5 mm, historically recognized as one
of the strongest risk factor for early SVG occlusion (16–18).
SVG occlusion also was more prevalent in subjects with both
CADP CT88 s and UTXB2450 pg/mg creatinine than in
subjects with CADP CT 88 s and UTXB2 450 pg/mg
reatinine (32% vs. 10%, respectively, p  0.0001). By
ultivariate analysis, this equated to a 6.9-fold increased
dds of SVG occlusion (95% confidence interval: 2.16 to
1.7, p  0.001) between groups.
asured 6 Months After CABG Surgery,iven ss, easured 6 Months After CABG Surgery,
Per Subject
Value >1 Occluded SVG No Occluded SVG n p Value
NS 0 (0–0) 0 (0–0) 228 NS
NS 17.7 5.5 17.8 4.8 212 NS
NS 17.8 4.8 17.7 5.1 209 NS
NS 16.4 5.3 17.1 4.4 224 NS
NS 5.20 5.76 5.50 6.45 227 NS
NS 15.1 5.1 14.8 5.2 228 NS
NS 288 (245–300) 300 (257–300) 226 NS
0.001 80 (71–95) 92 (77–110) 228 0.001
0.001 5.90 0.62 5.77 0.52 228 NS
NS 452 55 460 60 228 NS
Multivariate Models of Factors AssociatedWith Odds of SVG Occlusion Versus P t ncyTable 4 ultivariate Models of Fac ors AssociatedWith Odds of SVG Occlusion Versus Patency
Variable
Odds
Ratio p Value
95% Confidence
Interval
Model 1
PFA-100 CADP CT (s)* 0.98 0.002 0.97–0.99
Target vessel diameter 1.5 mm 2.36 0.009 1.23–4.53
UTXB2 (ln pg/mg creatinine)* 1.73 0.047 1.10–2.99
Female gender 2.31 0.052 0.99–5.39
Nonwhite race 2.48 0.059 0.97–6.38
Model 2
PFA-100 CADP CT (88 s vs. 88 s) 2.85 0.006 1.36–6.00
Target vessel diameter 1.5 mm 2.38 0.011 1.22–4.61
UTXB2 (450 pg/mg/creatinine vs.
450 pg/mg/creatinine)
2.59 0.015 1.20–5.56
Female sex 2.13 0.089 0.89–5.12, Mepons
p

*Odds of occlusion for every variable unit increase.
Abbreviations as in Tables 1 and 2.
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Despite advances in surgical technique and postoperative
management, including routine administration of ASA, the
incidence of early SVG occlusion after CABG surgery
remains substantial in a contemporary patient population.
The rate of SVG occlusion 6 months after CABG surgery
observed in the RIGOR study is consistent with results
from several recent studies, including the Project of Ex-vivo
Vein Graft Engineering via Transfection 4 trial, which
reported an overall SVG occlusion rate of 26% in 2400
patients 12 to 18 months after CABG surgery (19). Among
patient- and graft-specific variables associated with SVG
occlusion, bypass of small-diameter (1.5 mm) target
vessels historically has been considered one of the strongest
(17,18). In addition to this traditional risk factor, we
identified shear-dependent platelet activation, measured by
PFA-100 CADP CT, and ASA-insensitive TXA2 genera-
tion, measured by UTXB2, as potent novel independent risk
factors for early SVG thrombosis. The combination of
PFA-100 CADP CT and UTXB2 further was able to
stratify subjects into those at particularly high- and low-risk
for SVG thrombosis.
In normal individuals, the overwhelming majority of
TXA2 generated in the body is produced in platelets by
etabolism of arachidonic acid by the COX-1 enzyme.
ecause ASA efficiently and irreversibly inhibits platelet
OX-1 activity, it markedly suppresses TXA2 generation as
measured by UTXB2 and blunts platelet reactivity to several
gonists (15,20). Growing evidence suggests that some
atients with cardiovascular disease have persistent TXA2
generation despite ASA therapy and consequently are at
increased risk for adverse clinical events. This association
first was noted in a subgroup analysis from the Heart
Outcomes Prevention Evaluation study and later confirmed
in the larger Clopidogrel for High Atherothrombotic Risk
and Ischemic Stabilization, Management and Avoidance
trial, where subjects receiving ASA with the highest com-
pared with the lowest quartile of UTXB2 at study entry had
n approximate 1.7-fold increased risk (p  0.03 for both
tudies) of myocardial infarction, stroke, or cardiovascular
eath over the subsequent 2 to 5 years (8,9). Our findings
dd to the body of evidence suggesting that ASA-insensitive
XA2 generation is a significant cardiovascular risk factor
by demonstrating that it is associated independently with
early SVG occlusion after CABG surgery. Follow-up data
on RIGOR subjects currently are being collected to deter-
mine if ASA-insensitive TXA2 generation after CABG
urgery also adversely affects long-term clinical outcome.
A fundamental question arising from the above data is
hether ASA-insensitive TXA2 generation in patients with
ardiovascular disease represents a failure of ASA to inhibit
latelet COX-1–mediated TXA2 biosynthesis, the strictest
and most accurate definition of ASA resistance (5), or the
presence of alternate TXA2 production pathways that areot effectively inhibited by ASA. Zimmerman et al. (11)ound that platelets from patients taking 100 mg/day ASA
enerate more TXA2 in the first week after CABG surgery
han platelets from healthy ASA-treated controls. TXA2
generation was suppressed only partially by the further
exposure of platelets in vitro to high concentrations of ASA,
suggesting both incomplete COX-1 inhibition in vivo by
low-dose ASA, as well as the presence of COX-1–
independent TXA2 synthesis (10). Others subsequently
confirmed that platelets from ASA-treated subjects are
capable of generating TXA2 via non–COX-1–mediated
pathways, although the amounts are relatively small in
comparison with those produced by platelets from ASA-
naïve patients (21). Although we did not measure platelet
TXA2 generation directly in our study, arachidonic acid-
nduced platelet aggregation is known to be inhibited when
latelet TXA2 generation is suppressed by 90% (22). The
uppression of arachidonic acid-induced platelet aggrega-
ion in 95% of subjects both early and late after CABG
urgery argues for a high degree of platelet COX-1 inhibi-
ion by ASA, and therefore a very low prevalence of true
SA resistance in our study population.
Despite evidence for effective platelet COX-1 suppres-
ion by ASA, UTXB2 was elevated markedly in a substantial
umber of subjects both early and late after CABG surgery.
ecause UTXB2 reflects TXA2 generation in the entire
ody, not only from platelets, our data suggest that signif-
cant TXA2 production may originate from nonplatelet
sources that are not inhibited effectively by ASA. Potential
sources include inflammatory and endothelial cells that are
capable of producing TXA2 via both COX-1– and inducible
COX-2–dependent pathways. ASA is a relatively weak
inhibitor of COX-2 at standard doses (20), and unlike
platelets, both cell types have the capacity to regenerate
COX-1 that is irreversibly inhibited by ASA. Another
potential source is from nonenzymatic conversion of arachi-
donic acid to F2-isoprostanes under conditions of oxidative
tress. F2-isoprostanes are capable of activating platelet and
ellular TXA2 receptors and also can stimulate TXA2
production directly in endothelial cells (23,24). Additional
studies are needed to identify the sources of this ASA-
insensitive TXA2 generation and the mechanism by which
its production adversely affects clinical outcome.
Various aspects of platelet function, including ASA
responsiveness, can be characterized by a wide array of ex
vivo assays. One of the most physiologic is the PFA-100
device, which measures agonist-induced platelet aggrega-
tion under conditions of high shear by quantifying time to
closure of a membrane aperture by the formation of a
platelet plug (25). The PFA-100 was designed primarily to
screen for defects in primary hemostasis, with the CEPI
agonist cartridge detecting the antiplatelet effects of ASA
and the CADP agonist cartridge identifying patients with
congenital and acquired platelet disorders (26). Among
patients with cardiovascular disease, a CEPI CT in the
normal range (94 to 193 s) despite ASA therapy is associ-
ated with an increased risk of recurrent cardiovascular events
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the PFA-100 at detecting true ASA resistance has been
called into question by the observation that CEPI CTs are
highly influenced by plasma levels of von Willebrand factor
(29). Our results not only confirm the poor correlation
between ASA responsiveness defined by CEPI CT com-
pared with arachidonic acid-induced platelet aggregometry,
but also reveal no association between CEPI CT and SVG
outcome.
A major finding of our study was the strong association
between low CADP CT and early SVG occlusion. Unlike
CEPI CT, CADP CT is not influenced by ASA or
thienopyridine use and therefore is considered an indicator
of global platelet reactivity. Similar to CEPI CT, we found
a correlation between low CADP CT and high plasma von
Willebrand factor levels (13), but did not find an indepen-
dent association between von Willebrand factor levels and
early SVG occlusion (data not shown). A CADP CT below
the normal range (71 to 118 s) suggests platelet hyper-
reactivity and has been observed in patients with acute
coronary syndromes, where it correlated with the degree of
myocardial necrosis and recurrent ischemic events (30–32).
In a recent study of 700 patients undergoing percutaneous
coronary intervention, a CADP CT 65 s measured before
the procedure was associated with a 3.5-fold increase risk
(95% confidence interval: 1.2 to 10.4, p  0.03) of major
adverse cardiac events at 24 months (21). These studies,
along with our own, suggest the potential of measuring
shear-dependent platelet activation as a means to risk
stratify patients with cardiovascular disease.
Study limitations. A limitation of the RIGOR study was
that ASA responsiveness and platelet reactivity were not
assessed before surgery. This was by design because we
anticipated that not all eligible subjects would have been
receiving chronic ASA therapy before CABG surgery and
that some would have been receiving concurrent non-ASA
antiplatelet agents that would confound interpretation of
many of the assays. It was reasoned that values obtained 6
months after CABG surgery, after resolution of the associ-
ated inflammatory response and hematologic changes,
would be indicative of the subject’s baseline state. Now that
ASA-insensitive thromboxane generation and shear-
dependent platelet activation have been identified as impor-
tant parameters, additional studies will be needed to deter-
mine if their preoperative measurement can identify patients
at high risk for SVG thrombosis and what therapies might
be useful to mitigate such risk.
Conclusions
We have identified ASA-insensitive TXA2 generation,
measured by UTXB2, and shear-dependent platelet hyper-
eactivity, measured by PFA-100 CADP CT, as novel
ndependent risk factors for early SVG thrombosis. Both
ntities seem to represent pathways that are independent of
latelet COX-1 activity and are not inhibited effectively bySA. We further found that the prevalence of ASA
onresponsiveness varied widely by several commonly used
ssays and time relative to CABG surgery, but generally was
ot associated with graft outcome. Using arachidonic acid-
nduced platelet aggregometry as a specific indicator of
latelet TXA2 generation, however, the overwhelming ma-
jority of patients seem to have a high degree of platelet
COX-1 inhibition by ASA, and therefore a low incidence of
ASA resistance both early and late after CABG surgery.
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